#USA #Boston #CARB-X #Gonorrhea #AdJane

CARB-X Provides Major Funding to AdJane for Innovative Gonorrhea Vaccine

In a significant step towards combating one of the world’s most pressing public health threats, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has announced a $2.6 million grant to AdJane, a Netherlands-based biopharmaceutical company. This funding is aimed at advancing a new vaccine candidate designed to prevent infections caused by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, a highly prevalent sexually transmitted infection (STI).

The Urgency of Addressing Gonorrhea

Gonorrhea is not only one of the most commonly reported bacterial STIs globally, with more than 80 million new infections every year, but it also carries severe health implications such as pelvic inflammatory disease, infertility, and increased susceptibility to HIV infection. Many infections occur without noticeable symptoms, making it difficult for individuals to seek timely treatment, which exacerbates the spread of the disease. Due to its complex nature, the clinical management of gonorrhea is becoming increasingly challenging, primarily due to rising antibiotic resistance and limited treatment options.

AdJane's Innovative nOMV Platform

AdJane utilizes its innovative Native Outer Membrane Vesicle (nOMV) platform, which has been developed over 30 years through collaborations with leading Dutch research institutions. This platform allows for a heterologous approach that combines a broad antigenic background with targeted expression of conserved gonococcal antigens. The outcome is the generation of an effective and broad immune response against N. gonorrhoeae.

"We are excited to join the CARB-X portfolio and grateful for the support in realizing our vision to combat antimicrobial resistance through our platform," said Anita Gashi, CEO of AdJane. The funding acknowledges the potential of their next-generation nOMV platform to tackle global health challenges such as gonorrhea.

The Implications of CARB-X Funding

The grant from CARB-X not only supports the development of this vital vaccine but also signifies an ongoing commitment to strengthen global health security against antibiotic-resistant infections. Since its inception in 2016, CARB-X has provided backing for 123 early-stage projects across 14 countries, marking significant strides in the fight against resistant bacteria. As part of a broader initiative, the program ensures that all funded projects develop a stewardship and access plan, promoting responsible management and access in low- and middle-income countries.

Richard Alm, interim head of research and development at CARB-X, emphasized the importance of AdJane's approach, stating, “The clinical treatment of gonorrhea is becoming increasingly complex due to escalating antibiotic resistance. AdJane’s strategy addresses key challenges in generating protective immunity, which is crucial for reducing gonorrhea infection rates and slowing the spread of resistance.”

Future Prospects

Looking ahead, the nOMV platform will enhance vaccine development through three distinct administration modalities, catering to both prophylactic and therapeutic applications. As the fight against gonorrhea continues, the momentum gained from such funding will play a crucial role in public health efforts, highlighting the necessity for innovative solutions in the age of antibiotic resistance.

In conclusion, the partnership between AdJane and CARB-X exemplifies the collaborative efforts needed to tackle serious health threats like gonorrhea, paving the way for better prevention strategies against antibiotic-resistant infections. As research progresses, both organizations remain committed to improving global health outcomes and tackling the ongoing crisis of antibiotic resistance.